More importantly, blocking VEGFC/VEGFR3 signaling with a VEGFC‐neutralizing antibody or a specific VEGFR3 inhibitor reversed the enhancement of lymphangiogenesis and LN metastasis induced by LCN2 silencing in GC. The gene discussed is FLT4; the disease is gastric cancer.